Vilazodone and Restless Legs Syndrome
Yes, vilazodone can cause restless legs syndrome (RLS), and this is a documented adverse effect that should prompt consideration of medication discontinuation or switching to an alternative antidepressant.
Evidence from FDA Drug Label
The FDA-approved prescribing information for VIIBRYD (vilazodone) explicitly lists restlessness as an adverse reaction associated with overdose 1. While the label doesn't specifically list RLS as a common side effect in therapeutic dosing, restlessness is a recognized manifestation that can present as or evolve into RLS symptoms [@11,1].
Research Evidence on Vilazodone and Sleep Disorders
A comprehensive analysis of 77,391 patient reviews across 32 antidepressants found that vilazodone was associated with dramatically increased probability of developing RLS compared to other antidepressants 2. Specifically:
- Vilazodone heavily increased the probability of developing 5 out of 6 studied drug-induced sleep disorders (DISD), with proportional reporting ratios (PRR) ranging from 3.3 to 19.3 2
- This places vilazodone among the highest-risk antidepressants for causing RLS, alongside mirtazapine, venlafaxine, and tricyclic antidepressants [@14@]
In contrast, bupropion and citalopram showed lower probabilities for developing RLS (PRR 0.2 to 0.7) [@14@], making them safer alternatives if antidepressant therapy is still needed.
Clinical Reasoning
The mechanism by which vilazodone causes RLS likely relates to its serotonergic activity. As a selective serotonin reuptake inhibitor (SSRI) with 5-HT1A partial agonist properties, vilazodone enhances serotonergic neurotransmission [@12@]. Other SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs) are well-documented RLS triggers [@17@], and vilazodone appears to carry particularly high risk within this class.
Management Algorithm
If a patient on vilazodone develops RLS symptoms:
Confirm RLS diagnosis - Look for the four cardinal features:
- Urge to move legs with uncomfortable sensations
- Symptoms worse at rest/inactivity
- Relief with movement
- Symptoms worse in evening/night
Check iron status immediately - Measure ferritin and transferrin saturation before making treatment changes, as iron deficiency can coexist and is treatable [@1,3]
Discontinue or switch vilazodone - Given the strong association and high PRR, continuing vilazodone while treating RLS separately is not recommended
Switch to lower-risk antidepressant - Consider bupropion or citalopram, which have demonstrated lower RLS risk 2
If RLS persists after discontinuation, treat according to 2025 AASM guidelines:
Important Caveats
- Do not abruptly stop vilazodone - Taper gradually to avoid discontinuation syndrome, which can include irritability, dizziness, and other neurological symptoms 1
- The web-based data showing vilazodone's high RLS risk should be interpreted cautiously but aligns with known SSRI effects 2
- Some patients may experience RLS improvement simply from vilazodone discontinuation without needing specific RLS treatment 4
Bottom line: Vilazodone carries substantial risk for causing or worsening RLS. Switch to bupropion or citalopram for continued antidepressant therapy while addressing any underlying iron deficiency.